TMRW Life Sciences Raises $105M in Funding


TMRW Life Sciences, Inc., a NYC-based life sciences technology company providing an automated platform for tracking, monitoring, and storage of frozen eggs and embryos used in in vitro fertilization (IVF), completed a $105m Series C equity and debt financing.

The equity round was led by Transformation Capital with participation from GV (formerly Google Ventures), Casdin Capital, Peter Thiel, Anne and Susan Wojcicki, and existing investors 5AM Ventures and Life Sciences Innovation Fund, among others. In addition, the company’s debt partner Signature Bank increased their existing debt facility.

The company intends to use the funds to accelerate global expansion, advance product innovation, develop consumer awareness of the platform, and support future business development opportunities.

Led by Tara Comonte, CEO, TMRW has created an automated solution for how frozen eggs and embryos are stored, tracked, and monitored during the IVF process. The company uses RFID technology to make eggs and embryos traceable and safely maintained at cryogenic temperatures using robotics, 24/7 remote monitoring, and fully integrated software.

In the first six months since its commercial launch, TMRW has been adopted by prominent fertility clinics in the United States, including Vios Fertility Institute, Conceptions Reproductive Associates of Colorado, San Diego Fertility Center, Boston IVF, and Colorado Center for Reproductive Medicine (CCRM).